Do GLP-1 Analogs Have a Place in the Treatment of PCOS? New Insights and Promising Therapies

• Published in: Journal of clinical medicine 2023-09, Vol.12 (18), p.5915
• Main Authors: Szczesnowicz, Aleksandra, Szeliga, Anna, Niwczyk, Olga, Bala, Gregory, Meczekalski, Blazej
• Format: Article
• Language: English
• Subjects: Alfacalcidol; Alzheimer's disease; Antidiabetics; Appetite; Body weight; Calcifediol; Cardiovascular disease; Clinical medicine; Complications and side effects; Coronary vessels; Development and progression; Dextrose; Diabetes; Drug therapy; Food; GLP-1 receptor agonists; Glucagon; Glucose; Glucose metabolism; Glycosylated hemoglobin; Health aspects; Hormones; Hypertension; Hypoglycemia; Hypoglycemic agents; Insulin resistance; Levocarnitine; Metabolic diseases; Metabolic disorders; Metabolic syndrome; Obesity; Pancreatitis; Phosphorylation; Physiological aspects; Polycystic ovary syndrome; Review; Risk factors; Sleep apnea; Stein-Leventhal syndrome; Thyroid cancer; Type 2 diabetes; Vein & artery diseases; Vitamin D; Weight control; Weight loss; Womens health
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm12185915

Polycystic ovary syndrome (PCOS) is the most prevalent endocrinopathy in women of reproductive age. This condition is characterized by hyperandrogenism and either oligo- or anovulation. PCOS patients often present comorbidities such as obesity, insulin resistance, impaired glucose metabolism, dyslipidemia, hypertension, metabolic syndrome, and an increased risk of diabetes. Given the profound implications of metabolic impairment in PCOS, the accurate diagnosis and management of these facets are imperative. The first-line approach to treatment involves lifestyle modifications, including dietary adjustments and exercise aimed at achieving weight loss, a strategy consistently emphasized across the literature. Supplementation with probiotics, vitamin D, and L-carnitine have also provided additional benefits to patients. In select cases, pharmacological interventions are needed for optimal therapeutic results. The most common medications used in PCOS include metformin, thiazolidinediones, inositols, and two classes of antidiabetic agents: dipeptidyl peptidase-IV (DPP-IV) inhibitors, and sodium–glucose cotransporter-2 (SGLT-2) inhibitors. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a new addition to the therapeutic arsenal for the metabolic management of PCOS. GLP-1 receptor agonists cause insulin release in a glucose-dependent manner, yielding clinical benefits such as heightened satiety, reduced appetite, and appetite regulation. GLP-1RAs have demonstrated efficacy in reducing glycated hemoglobin levels and promoting weight loss while ameliorating hyperlipidemia. Prior to initiating GLP-1RA therapy, patients should undergo screening for contraindications, including history of pancreatitis, diabetic retinopathy, or thyroid cancer. The effects of treatment should be monitored using laboratory testing and body weight measurements. Effective communication between clinician and patient should be maintained with regular check-in for a period of 6 to 12 months.